Tuberculosis lymphadenitis in ethiopia.

Tuberculosis lymphadenitis in ethiopia. Jpn J Infect Dis. 2013;66(4):263-8 Authors: Biadglegne F, Tesfaye W, Anagaw B, Tessema B, Debebe T, Anagaw B, Mulu A, Sack U, Rodloff AC Abstract Tuberculosis (TB) is one of the most serious public health challenges in Ethiopia. Indeed, Ethiopia ranks 7th among 22 countries with a high burden of TB worldwide. Both pulmonary TB and extrapulmonary TB (EPTB) are issues of concern. Ethiopia ranks 3rd in terms of the number of EPTB patients worldwide, with TB lymphadenitis (TBL) being the most common. According to the World Health Organization's Global TB Report 2009, the estimated number of TB patients in Ethiopia was 314,267 in 2007, with an estimated incidence rate of 378 patients per 100,000 population. Furthermore, 36% patients suffered from EPTB, with TBL accounting for 80% of these patients. In Ethiopia, pathological services, culture, and drug susceptibility testing for mycobacterium species are not available as routine tests, not even for cases with suspected infection by drug-resistant strains. Therefore, the management of multidrug-resistant (MDR) TB in Ethiopia is currently unsatisfactory. Against this background, a high index of clinical doubt and timely use of diagnostic methods, prompt confirmation of diagnosis, and early initiation of specific anti-TB treatment are the key factors for the successful management of MDR-TB and TBL in Ethiopia. PMID: 23883834 [PubMed - in process]
Source: Japanese Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Jpn J Infect Dis Source Type: research

Related Links:

Conclusions: AEs were common, but not more frequent or severe among MDR-TB/HIV co-infected participants receiving concurrent antiretroviral therapy. Given the favorable treatment outcomes associated with concurrent treatment, antiretroviral therapy initiation should not be delayed in MDR-TB patients with HIV-coinfection.
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - Category: Infectious Diseases Tags: Clinical Science Source Type: research
ido A Abstract Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and represents one of the leading causes of mortality worldwide due to multidrug-resistant TB (MDR-TB). In our work, a new formulation of biodegradable PLGA microparticles was developed for pulmonary administration of gatifloxacin, using a surface modifier agent to actively target alveolar macrophages thereby allowing to gain access of the drug to Mycobacterium tuberculosis. For this, rapid uptake of the particles by macrophages is beneficial. This process was evaluated with fluorescein-loaded microparticles using PLGA 5...
Source: AAPS PharmSciTech - Category: Drugs & Pharmacology Authors: Tags: AAPS PharmSciTech Source Type: research
ConclusionsOur study provides the first insight into molecular epidemiology of MDR-TB in Kuwait and identified several potential clusters of local transmission of MDR-TB involving 2 –6 subjects which had escaped detection by routine surveillance studies. Prospective detection of resistance-conferring mutations can identify possible cases of local transmission of MDR-TB in low MDR-TB settings.
Source: European Journal of Medical Research - Category: Research Source Type: research
Despite all our efforts, the disease burden of tuberculosis (TB) is not falling fast enough to reach the 2030 milestone of the End TB strategy [1]. Multidrug-resistant tuberculosis (MDR-TB) remains a public health crisis, with low treatment success rates [1]. The repurposed drug linezolid has emerged as a core drug in MDR-TB treatment regimens [2, 3], despite its toxicity, e.g. anaemia, peripheral neuropathy and gastrointestinal disorders, optic neuritis, and thrombocytopenia [4, 5]. Currently, linezolid is used off-label, as part of Group A "Medicines to be prioritised" of the World Health Organization (WHO) MDR...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: Research letters Source Type: research
ConclusionOur results show strong bactericidal potential of CHP against M.tuberculosis that warrant its immediate mechanistic, pharmacokinetic and pharmacodynamic studies.Graphical abstract
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
CYCLOSERINE ENANTIOMERS ARE REVERSIBLE INHIBITORS OF HUMAN ALANINE:GLYOXYLATE AMINOTRANSFERASE: IMPLICATIONS FOR PRIMARY HYPEROXALURIA TYPE 1. Biochem J. 2019 Dec 03;: Authors: Dindo M, Grottelli S, Annunziato G, Giardina G, Pieroni M, Pampalone G, Faccini A, Cutruzzolà F, Laurino P, Costantino G, Cellini B Abstract Peroxisomal alanine:glyoxylate aminotransferase (AGT) is responsible for glyoxylate detoxification in human liver and utilizes pyridoxal 5'-phosphate (PLP) as coenzyme. The deficit of AGT leads to Primary Hyperoxaluria Type I (PH1), a rare disease characterized by calcium oxalate st...
Source: The Biochemical Journal - Category: Biochemistry Authors: Tags: Biochem J Source Type: research
ConclusionWGS ofM. tuberculosis isolates allows the detection of drug resistance to all drugs in a single test and also provides insight into the evolution and drug-resistant TB.
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
Sandra Gemma Tuberculosis (TB) is one of the top 10 causes of death worldwide. This scenario is further complicated by the insurgence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB. The identification of appropriate drugs with multi-target affinity profiles is considered to be a widely accepted strategy to overcome the rapid development of resistance. The aim of this study was to discover Food and Drug Administration (FDA)-approved drugs possessing antimycobacterial activity, potentially coupled to an effective multi-target profile. An integrated screening platform was implemented based on comput...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
This study is the first to identify specific metabolome variations related to the addition of Tween 80 to the growth media during M. tuberculosis culturing. The consideration of these results during the method development and data interpretation phases of future metabolomics investigations will improve the quality of the analyses as well as the credibility of potential research outcomes. These results will also assist in the interpretation of research questions specifically aimed at aspects of mycobacterial metabolism, even when using other methodologies such as transcriptomics or fluxomics.
Source: Journal of Microbiological Methods - Category: Microbiology Source Type: research
Conditions:   Tuberculosis, Pulmonary;   Tuberculosis, Multidrug-Resistant;   Tuberculosis, MDR;   Tuberculosis;   Drug-Resistant Tuberculosis Intervention:   Drug: Pretomanid Sponsor:   Global Alliance for TB Drug Development Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Ethiopia Health | Infectious Diseases | International Medicine & Public Health | Multidrug Resistance | Tuberculosis | WHO